Your browser is no longer supported. Please, upgrade your browser.
NovaBay Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own9.60% Shs Outstand40.04M Perf Week28.78%
Market Cap42.71M Forward P/E- EPS next Y-0.15 Insider Trans-25.12% Shs Float31.25M Perf Month52.94%
Income-12.80M PEG- EPS next Q-0.05 Inst Own6.20% Short Float3.28% Perf Quarter41.82%
Sales9.80M P/S4.36 EPS this Y-25.30% Inst Trans- Short Ratio0.54 Perf Half Y-35.40%
Book/sh0.35 P/B2.97 EPS next Y53.10% ROA-100.10% Target Price- Perf Year65.57%
Cash/sh0.33 P/C3.19 EPS next 5Y- ROE-329.80% 52W Range0.24 - 1.94 Perf YTD49.21%
Dividend- P/FCF- EPS past 5Y42.40% ROI-261.30% 52W High-46.39% Beta3.78
Dividend %- Quick Ratio5.10 Sales past 5Y44.30% Gross Margin61.50% 52W Low333.33% ATR0.09
Employees28 Current Ratio5.30 Sales Q/Q37.50% Oper. Margin-70.30% RSI (14)69.72 Volatility15.71% 9.94%
OptionableNo Debt/Eq0.01 EPS Q/Q-558.90% Profit Margin- Rel Volume3.14 Prev Close0.91
ShortableYes LT Debt/Eq0.00 EarningsNov 12 AMC Payout- Avg Volume1.90M Price1.04
Recom1.50 SMA2037.22% SMA5053.35% SMA20019.84% Volume5,970,508 Change13.89%
Sep-18-19Initiated Ladenburg Thalmann Buy $1.10
Jul-06-18Reiterated H.C. Wainwright Buy $4
Nov-15-17Reiterated Laidlaw Buy $10 → $8
Jun-05-17Initiated ROTH Capital Buy $5.50
Mar-27-17Initiated Laidlaw Buy $10
Feb-06-17Initiated Rodman & Renshaw Buy $6
Mar-07-16Downgrade Maxim Group Buy → Hold
Dec-14-15Reiterated Maxim Group Buy $1 → $0.23
Apr-30-15Resumed Maxim Group Buy $2
Mar-06-13Initiated Ascendiant Capital Markets Strong Buy $2.25
Jan-03-08Initiated Dawson James Speculative Buy $8
Dec-14-20 06:50AM  
Nov-23-20 06:50AM  
Nov-12-20 04:05PM  
Nov-03-20 04:11PM  
Oct-30-20 06:50AM  
Oct-12-20 06:50AM  
Sep-24-20 06:50AM  
Sep-08-20 06:50AM  
Aug-24-20 06:50AM  
Aug-18-20 12:05PM  
Aug-06-20 04:05PM  
Jul-27-20 06:50AM  
Jul-13-20 06:50AM  
May-14-20 06:50AM  
May-07-20 04:05PM  
May-05-20 02:05PM  
Apr-27-20 04:15PM  
Apr-20-20 06:50AM  
Mar-26-20 04:05PM  
Mar-25-20 06:50AM  
Mar-23-20 06:50AM  
Mar-19-20 06:50AM  
Dec-02-19 06:50AM  
Nov-18-19 06:50AM  
Nov-07-19 04:05PM  
Nov-04-19 06:50AM  
Oct-31-19 06:50AM  
Oct-28-19 06:50AM  
Sep-24-19 02:20PM  
Sep-16-19 06:50AM  
Aug-09-19 09:26AM  
Aug-07-19 06:50AM  
Jul-29-19 06:50AM  
Jul-15-19 06:50AM  
Jul-01-19 10:17AM  
Jun-26-19 04:05PM  
Jun-17-19 06:50AM  
Jun-10-19 01:52PM  
May-21-19 04:05PM  
May-09-19 04:05PM  
Apr-30-19 06:50AM  
Apr-17-19 06:50AM  
Apr-15-19 06:50AM  
Mar-28-19 04:05PM  
Mar-12-19 04:05PM  
Jan-07-19 06:50AM  
Nov-14-18 04:05PM  
Nov-07-18 06:50AM  
Nov-06-18 10:30AM  
Sep-28-18 06:50AM  
Aug-30-18 08:00AM  
Aug-07-18 04:05PM  
Jul-31-18 06:50AM  
Jul-05-18 06:50AM  
May-10-18 04:05PM  
May-07-18 06:50AM  
Mar-20-18 04:05PM  
Mar-01-18 10:49PM  
Feb-21-18 06:50AM  
Feb-12-18 06:50AM  
Jan-08-18 06:50AM  
Dec-22-17 06:50AM  
Dec-21-17 06:50AM  
Dec-19-17 01:41PM  
Dec-06-17 06:50AM  
Nov-30-17 02:09PM  
Nov-29-17 08:02AM  
Nov-14-17 04:05PM  
Nov-07-17 06:50AM  
Sep-26-17 09:00AM  
Sep-20-17 06:50AM  
Sep-19-17 06:10PM  
Sep-18-17 12:01PM  
Sep-05-17 06:50AM  
Aug-14-17 09:00AM  
Aug-10-17 04:05PM  
Aug-03-17 06:50AM  
Jul-24-17 10:00AM  
Jul-10-17 01:32PM  
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WU MIJIADirectorAug 17Sale1.3520,00027,0000Aug 19 04:24 PM
Fu Jian Ping10% OwnerAug 01Sale1.231,302,3501,601,8914,000,000Aug 04 06:04 PM